SFM
ADVM

Sphera Funds Management’s Adverum Biotechnologies ADVM Stock Holding History

Sphera Funds Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,336
Closed -$200K – 107
2018
Q4 		$200K Sell
6,336
-1,164
-16% -$47.3K 0.02% 98
2018
Q3 		$454K Buy
+7,500
New +$421K 0.05% 100
2015
Q2 		– Sell
-6,000
Closed -$2.43M – 130
2015
Q1 		$2.43M Buy
+6,000
New +$2.54M 0.25% 97

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Sphera Funds Management's ADVM Position: Q1 2019 in Review

Sphera Funds Management sold out of Adverum Biotechnologies (ADVM) in Q1 2019, closing a stake of 6,336 shares — an estimated $200K sold.

Sphera Funds Management first reported a position in ADVM in Q1 2015 and held it in 3 quarters. The position peaked at $2.43M in Q1 2015. 83 funds tracked by Wall St. Rank hold ADVM as of Q1 2019.

  • Sphera Funds Management reported no remaining Adverum Biotechnologies position as of Q1 2019 after selling out during the quarter.
  • Sphera Funds Management sold 6,336 Adverum Biotechnologies shares in Q1 2019, an estimated $200K.
  • Sphera Funds Management first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 3 quarters.
  • Sphera Funds Management's Adverum Biotechnologies position peaked at $2.43M in Q1 2015.
  • 83 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2019.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.